Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., . . . Pazdur, R. (2017). FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy. Oncologist.
Chicago Stili AlıntıLarkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Disease Progression On or After Platinum‐Containing Chemotherapy." Oncologist 2017.
MLA AlıntıLarkins, Erin, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Disease Progression On or After Platinum‐Containing Chemotherapy." Oncologist 2017.